lansoprazole brands
4 registered brands containing lansoprazole in Botswana.
Lansoprazole
PubChem CID 3883Molecular formula: C16H14F3N3O2S
As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides. PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets. Lansoprazole is a selective and irreversible proton pump inhibitor. In the acidic environment of the gastric parietal cell, lansoprazole is converted to active sulphenamide derivatives that bind to the sulfhydryl group of (H+, K+)-adenosine triphosphatase ((H+,K+)-ATPase), also known as the proton pump (H+,K+)-ATPase catalyzes the final step in the gastric acid secretion pathway. Lansoprazole's inhibition of (H+,K+)-ATPase results in inhibition of both centrally and peripherally mediated gastric acid secretion. The inhibitory effect is dose-related. Lansoprazole inhibits both basal and stimulated gastric acid secretion regardless of the stimulus.
Source: PubChem (NCBI) ยท compound 3883
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| INNAVACID 15 DELAYED RELEASE CAPSULES |
Inventia Healthcare | Registered/Compliant | Botswana |
| INNAVACID 30 DELAYED RELEASE CAPSULES |
Inventia Healthcare | Registered/Compliant | Botswana |
| RAN-LANSOPRAZOLE 15 CAPSULE |
Sun Pharmaceutical Industries Limited | Registered/Compliant | Botswana |
| RAN-LANSOPRAZOLE 30 CAPSULE |
Sun Pharmaceutical Industries Limited | Registered/Compliant | Botswana |